Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 9050828, 10 pages
http://dx.doi.org/10.1155/2016/9050828
Research Article

Melatonin Attenuates Contrast-Induced Nephropathy in Diabetic Rats: The Role of Interleukin-33 and Oxidative Stress

1Department of Anesthesiology and Reanimation, Faculty of Medicine, Erzincan University, Erzincan, Turkey
2Department of Cardiovascular Surgery, Faculty of Medicine, Erzincan University, Erzincan, Turkey
3Division of Nephrology, Department of Internal Medicine, Meram School of Medicine, Necmettin Erbakan University, Meram Tıp Fakültesi No. 215, Meram, 42090 Konya, Turkey
4Department of Biochemistry, Faculty of Veterinary, Ataturk University, Erzurum, Turkey
5Department of Anesthesiology and Reanimation, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey
6Department of Histology and Embryology, Faculty of Medicine, Ataturk University, Erzurum, Turkey
7Department of Cardiology, Faculty of Medicine, Erzincan University, Erzincan, Turkey

Received 25 November 2015; Revised 21 January 2016; Accepted 27 January 2016

Academic Editor: Muzamil Ahmad

Copyright © 2016 Didem Onk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. A. Lopes, “End-stage renal disease due to diabetes in racial/ethnic minorities and disadvantaged populations,” Ethnicity & Disease, vol. 19, no. 1, supplement 1, pp. S1–S47, 2009. View at Google Scholar
  2. American Diabetes Association, “Economic costs of diabetes in the U.S. In 2007,” Diabetes Care, vol. 31, no. 3, pp. 596–615, 2008. View at Publisher · View at Google Scholar
  3. J. S. Skyler and C. Oddo, “Diabetes trends in the USA,” Diabetes/Metabolism Research and Reviews, vol. 18, supplement 3, pp. S21–S26, 2002. View at Google Scholar · View at Scopus
  4. M. Sanaei-Ardekani, M.-R. Movahed, S. Movafagh, and N. Ghahramani, “Contrast-induced nephropathy: a review,” Cardiovascular Revascularization Medicine, vol. 6, no. 2, pp. 82–88, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Mehran, E. D. Aymong, E. Nikolsky et al., “A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation,” Journal of the American College of Cardiology, vol. 44, no. 7, pp. 1393–1399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Goldenberg and S. Matetzky, “Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies,” Canadian Medical Association Journal, vol. 172, no. 11, pp. 1461–1471, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Elmarakby and J. C. Sullivan, “Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy,” Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Akcay, Q. Nguyen, Z. He et al., “IL-33 exacerbates acute kidney injury,” Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2057–2067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Lu, J. Kang, C. Zhang, and X. Zhang, “The role of IL-33/ST2L signals in the immune cells,” Immunology Letters, vol. 164, no. 1, pp. 11–17, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Gazi, A. Altun, and O. Erdogan, “Contrast-induced nephropathy: preventive and protective effects of melatonin,” Journal of Pineal Research, vol. 41, no. 1, pp. 53–57, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at Publisher · View at Google Scholar · View at Scopus
  12. P. P. Bradley, R. D. Christensen, and G. Rothstein, “Cellular and extracellular myeloperoxidase in pyogenic inflammation,” Blood, vol. 60, no. 3, pp. 618–622, 1982. View at Google Scholar · View at Scopus
  13. Y. Sun, L. W. Oberley, and Y. Li, “A simple method for clinical assay of superoxide dismutase,” Clinical Chemistry, vol. 34, no. 3, pp. 497–500, 1988. View at Google Scholar · View at Scopus
  14. H. Aebi, “Catalase in vitro,” in Methods in Enzymology, vol. 105, chapter 13, pp. 121–126, Academic Press, New York, NY, USA, 1984. View at Publisher · View at Google Scholar
  15. J. Sedlak and R. H. Lindsay, “Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent,” Analytical Biochemistry, vol. 25, pp. 192–205, 1968. View at Publisher · View at Google Scholar · View at Scopus
  16. G. L. Bakris, N. A. Lass, and D. Glock, “Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors,” Kidney International, vol. 56, no. 1, pp. 206–210, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Brezis and S. Rosen, “Hypoxia of the renal medulla—its implications for disease,” The New England Journal of Medicine, vol. 332, no. 10, pp. 647–655, 1995. View at Publisher · View at Google Scholar · View at Scopus
  18. M. M. Anwar and A.-R. M. A. Meki, “Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin,” Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, vol. 135, no. 4, pp. 539–547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Zephy and J. Ahmad, “Type 2 diabetes mellitus: role of melatonin and oxidative stress,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 9, no. 2, pp. 127–131, 2015. View at Publisher · View at Google Scholar
  20. A. Fornoni, A. Ijaz, T. Tejada, and O. Lenz, “Role of inflammation in diabetic nephropathy,” Current Diabetes Reviews, vol. 4, no. 1, pp. 10–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Moriwaki, T. Yamamoto, Y. Shibutani et al., “Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy,” Metabolism: Clinical and Experimental, vol. 52, no. 5, pp. 605–608, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” The Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Moussion, N. Ortega, and J.-P. Girard, “The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?” PLoS ONE, vol. 3, no. 10, Article ID e3331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Lamkanfi and V. M. Dixit, “IL-33 raises alarm,” Immunity, vol. 31, no. 1, pp. 5–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Milovanovic, V. Volarevic, G. Radosavljevic et al., “IL-33/ST2 axis in inflammation and immunopathology,” Immunologic Research, vol. 52, no. 1-2, pp. 89–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Zdravkovic, A. Shahin, N. Arsenijevic, M. L. Lukic, and E. P. K. Mensah-Brown, “Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin,” Molecular Immunology, vol. 47, no. 1, pp. 28–36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. S. G. Karatas, H. Yilmaz, Z. Firat et al., “Role of the inflammasome and interleukin-33 in diabetic nephropathy pathogenesis,” JASN Abstract Supplement, PUB301, ASN Kidney Week, p. 25, 2014.
  28. R. Kakkar and R. T. Lee, “The IL-33/ST2 pathway: therapeutic target and novel biomarker,” Nature Reviews Drug Discovery, vol. 7, no. 10, pp. 827–840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Dinarello, “An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor,” Immunity, vol. 23, no. 5, pp. 461–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Hu, Z. Ma, S. Jiang et al., “Melatonin: the dawning of a treatment for fibrosis?” Journal of Pineal Research, vol. 60, no. 2, pp. 121–131, 2016. View at Publisher · View at Google Scholar
  31. E. Ozbek, Y. O. Ilbey, M. Ozbek, A. Simsek, M. Cekmen, and A. Somay, “Melatonin attenuates unilateral ureteral obstruction-induced renal injury by reducing oxidative stress, iNOS, MAPK, and NF-kB expression,” Journal of Endourology, vol. 23, no. 7, pp. 1165–1173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Ogeturk, I. Kus, A. Kavakli, J. Oner, A. Kukner, and M. Sarsilmaz, “Reduction of carbon tetrachloride-induced nephropathy by melatonin administration,” Cell Biochemistry and Function, vol. 23, no. 2, pp. 85–92, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. C. L. Manske, J. M. Sprafka, J. T. Strony, and Y. Wang, “Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography,” The American Journal of Medicine, vol. 89, no. 5, pp. 615–620, 1990. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Rodriguez, J. C. Mayo, R. M. Sainz et al., “Regulation of antioxidant enzymes: a significant role for melatonin,” Journal of Pineal Research, vol. 36, no. 1, pp. 1–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Srinivasan, G. J. M. Maestroni, D. P. Cardinali, A. I. Esquifino, S. R. Pandi Perumal, and S. C. Miller, “Melatonin, immune function and aging,” Immunity and Ageing, vol. 2, article 17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. G. J. M. Maestroni, “The immunotherapeutic potential of melatonin,” Expert Opinion on Investigational Drugs, vol. 10, no. 3, pp. 467–476, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. S. García-Mauriño, D. Pozo, A. Carrillo-Vico, J. R. Calvo, and J. M. Guerrero, “Melatonin activates Th1 lymphocytes by increasing IL-12 production,” Life Sciences, vol. 65, no. 20, pp. 2143–2150, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. P. O. Castrillón, A. I. Esquifino, A. Varas, A. Zapata, R. A. Cutrera, and D. P. Cardinali, “Effect of melatonin treatment on 24-h variations in responses to mitogens and lymphocyte subset populations in rat submaxillary lymph nodes,” Journal of Neuroendocrinology, vol. 12, no. 8, pp. 758–765, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Garcia-Mauriño, M. G. Gonzalez-Haba, J. R. Calvo et al., “Melatonin enhances IL-2, IL-6, and IFN-γ production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes,” The Journal of Immunology, vol. 159, no. 2, pp. 574–581, 1997. View at Google Scholar · View at Scopus
  40. K. M. Morrey, J. A. McLachlan, C. D. Serkin, and O. Bakouche, “Activation of human monocytes by the pineal hormone melatonin,” The Journal of Immunology, vol. 153, no. 6, pp. 2671–2680, 1994. View at Google Scholar · View at Scopus
  41. V. Raghavendra, V. Singh, S. K. Kulkarni, and J. N. Agrewala, “Melatonin enhances Th2 cell mediated immune responses: lack of sensitivity to reversal by naltrexone or benzodiazepine receptor antagonists,” Molecular and Cellular Biochemistry, vol. 221, no. 1-2, pp. 57–62, 2001. View at Publisher · View at Google Scholar · View at Scopus